I've contacted Beverly (investor relations) regarding the royalty split. She mentioned that it is a bit confusing. But, Alimera states that the royalty represents essentially a 14% to 15% of net sales. AND...pSivida has full audit rights. The important part of the equation of course is that we will be seeing revenue.
mickmack, Guess you are talking about the European countries. Do you know what the expected yearly revenue total at 15% would come to? IFor us long term longs, it is nice to see volume and sp increase, but also do it in a strong manner over weeks instead of those pump and dumps from last year.
Mo, I think we're through some of the rough times post CRL's. Eventually, the beatings stop, and those shorts even cover and sometimes go long. We have a lot of upside pending and everyone knows it. SP goes can be all over the place, but if you just hold for the PIII Uveitis results and be patient, we'll have some real catalysts to move SP big. Obviously, I'm a big believer in PSDV, and have a large position. In two years we'll be on the map in a big way. I think we have really great management. To answer your question about revenue, I don't really know how they are going to determine "net" and the percentage of it. Beverly at IR, says it is very clearly defined.